샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794502

세계의 다발성골수종 치료제 시장

Multiple Myeloma Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 274 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 다발성골수종 치료제 시장은 2030년까지 286억 달러에 달할 전망

2024년에 212억 달러로 추정된 세계의 다발성골수종 치료제 시장은 2024-2030년의 분석 기간에 CAGR 5.1%로 성장하며, 2030년에는 286억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 표적치료는 CAGR 4.2%를 기록하며, 분석 기간 종료시에는 110억 달러에 달할 것으로 예측됩니다. 생물학적 요법 분야의 성장률은 분석 기간 중 CAGR 6.6%로 추정됩니다.

미국 시장은 58억 달러로 추정, 중국은 CAGR 8.0%로 성장 예측

미국의 다발성골수종 치료제 시장은 2024년에 58억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 8.0%로 추이하며, 2030년에는 예측 시장 규모가 56억 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.6%와 5.1%로 예측됩니다. 유럽에서는 독일이 CAGR 3.3%로 성장할 것으로 예측됩니다.

세계의 다발성골수종 치료제 시장 - 주요 동향과 촉진요인 정리

다발성골수종 치료제 개발이 빠르게 진행되는 이유

다발성골수종은 복잡한 병태와 재발성으로 인해 여전히 가장 활발하게 연구되고 있는 혈액암 중 하나입니다. 다발성골수종은 대부분의 경우 불치병이지만, 약물 개발의 발전으로 질병 관리와 환자 생존율이 크게 향상되었습니다. 현재는 면역조절제, 프로테아좀 억제제, 모노클로널 항체, 부신피질 스테로이드 등을 병용하는 치료법이 시행되고 있습니다. 이러한 조합은 도입 요법, 유지 요법, 재발 치료 요법의 골격을 형성하고 있습니다. 새로운 약제군별 및 표적 치료는 신규 진단 환자 및 난치성 환자 모두에 대한 치료의 전망을 넓히고 있습니다.

치료 목표는 관해 확대, 재발 지연, 정확한 부작용 관리 등입니다. 유전자 마커, 세포유전학적 위험도, 치료 전 효과에 기반한 개별화 요법이 보편화되고 있습니다. 3제 병용요법, 4제 병용요법, 적격 환자에게 줄기세포 이식을 사용하는 사례가 증가하고 있는 것은 독성을 최소화하면서 지속적인 반응을 얻기 위한 진화한 임상 전략을 반영합니다. 다발성골수종은 매우 불균일하므로 치료법 선택은 점점 더 환자별 질병 특성과 내약성 프로파일을 반영하고 있습니다.

차세대 다발성골수종 치료는 어떤 혁신으로 형성되고 있는가?

최근 혁신 기술로는 CD38, SLAMF7과 같은 표면 항원을 표적으로 하는 단클론 항체를 도입하여 골수종 세포의 면역 매개성 사멸을 강화하는 것이 있습니다. 이 약제들은 종종 기존 치료법과 병용하여 무진행생존기간에 유의미한 개선을 보였으며, 무진행생존기간도 유의하게 개선되었습니다. 이중특이적 T세포유전자(BiTE)와 항체-약물 접합체(ADC)도 면역반응을 이용하면서 종양세포에 직접 관여하는 능력에 대해 연구되고 있습니다.

CAR T 세포 치료와 같은 세포 기반 치료는 중증 전치 및 재발 환자들을 위한 주요 관심 분야가 되고 있습니다. 이 치료법은 골수종 특이 항원을 표적으로 하는 환자 자신의 T세포를 공학적으로 만들어내는 치료법입니다. 현재 진행 중인 임상시험에서 치료 초기 단계의 가능성을 평가하고 있으며, 현재 진행 중인 임상시험에서는 진행성 질환에만 적용되고 있습니다. 경구용 프로테아좀 억제제 및 2세대 면역조절제는 특히 장기 유지요법에서 편의성 향상과 부작용 감소를 목표로 개발되고 있습니다.

수요를 주도하는 환자 부문과 헬스케어 환경은?

재발 및 난치성 환자는 가장 빠르게 성장하고 있는 치료 분야로 새로운 작용기전을 가진 새로운 약물이 필요한 분야입니다. 고령의 환자나 합병증이 있는 환자들은 더 낮은 강도의 요법을 필요로 하는 경우가 많아 병원 밖에서 투여할 수 있는 경구제나 피하주사제에 대한 수요가 발생하고 있습니다. 외래 수액 센터, 전문 약국, 재택치료 서비스 프로바이더는 특히 치료 기간이 수개월에서 수년으로 늘어남에 따라 치료 제공에 더 많이 관여하고 있습니다.

진단의 개선으로 조기 발견과 위험도 분류가 가능해져 고위험군 환자들에 대한 조기 개입이 가능해졌습니다. 골질환, 신장 기능 장애, 치료 관련 부작용을 관리하기 위한 지지요법도 개선되어 병용 요법에 대한 폭넓은 접근이 가능해졌습니다. 지불자와 의료 서비스 프로바이더는 가치 기반 치료를 중시하고, 허용 가능한 독성 프로파일로 장기적인 질병 통제를 보여주는 치료법에 초점을 맞추었습니다. 이러한 변화는 전 세계 포뮬러리에 대한 통합 및 환자 접근 전략에 영향을 미치고 있습니다.

다발성골수종 치료제 시장의 성장은 몇 가지 요인에 의해 주도됩니다.

다발성골수종 치료제 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 전 세계 유병률 증가, 특히 고령화 사회의 유병률 증가로 인해 치료 대상이 확대되고 있습니다. 면역치료제, 세포치료제, 표적치료제의 끊임없는 기술 혁신이 임상 도입과 적응증 확대를 촉진하고 있습니다. 진단 정확도의 향상으로 위험에 맞는 치료 계획을 세울 수 있게 되면서 1차 치료와 구제 치료 모두에 대한 수요가 증가하고 있습니다. 외래 치료와 재택 치료로의 전환으로 경구제 및 피하주사제 사용이 증가했습니다. 병용요법 및 유지요법이 받아들여지고, 치료 기간이 연장되며, 수요가 지속됩니다. 바이오제약 기업의 파이프라인 개발 및 임상시험에 대한 투자로 지역 간 시장 확대가 더욱 가속화됨.

부문

치료법(표적치료, 생물학적 요법, 화학요법, 기타 치료법), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업의 예

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Idec
  • bluebird bio, Inc.
  • Bristol-Myers Squibb(Celgene)
  • Cipla Inc.
  • Daiichi Sankyo
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson(Janssen)
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Seagen(Pfizer subsidiary)
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Multiple Myeloma Drugs Market to Reach US$28.6 Billion by 2030

The global market for Multiple Myeloma Drugs estimated at US$21.2 Billion in the year 2024, is expected to reach US$28.6 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Biologic Therapy segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 8.0% CAGR

The Multiple Myeloma Drugs market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.6 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Multiple Myeloma Drugs Market - Key Trends & Drivers Summarized

Why Is Drug Development for Multiple Myeloma Advancing Rapidly?

Multiple myeloma remains one of the most actively researched hematologic cancers due to its complex pathology and recurring nature. While it remains incurable in most cases, advances in drug development have led to significant improvements in disease management and patient survival. Therapeutic approaches now combine immunomodulators, proteasome inhibitors, monoclonal antibodies, and corticosteroids. These combinations form the backbone of induction, maintenance, and relapsed therapy regimens. New drug classes and targeted therapies are expanding the treatment landscape for both newly diagnosed and refractory patients.

Treatment goals include deepening remission, delaying relapse, and managing side effects with improved precision. Personalized regimens are becoming common, based on genetic markers, cytogenetic risk, and prior response. The growing use of triplet and quadruplet regimens, as well as stem cell transplantation in eligible patients, reflects an evolving clinical strategy that seeks durable responses while minimizing toxicity. As multiple myeloma is highly heterogeneous, therapeutic choices increasingly reflect patient-specific disease characteristics and tolerance profiles.

What Innovations Are Shaping the Next Generation of Multiple Myeloma Therapies?

Recent innovations include the introduction of monoclonal antibodies targeting surface antigens such as CD38 and SLAMF7, which enhance immune-mediated killing of myeloma cells. These agents, often combined with established therapies, have shown meaningful improvements in progression-free survival. Bispecific T-cell engagers (BiTEs) and antibody-drug conjugates (ADCs) are also being studied for their ability to directly engage tumor cells while harnessing immune response.

Cell-based therapies such as CAR T-cell treatments have become a major area of interest for heavily pretreated or relapsed patients. These therapies involve engineering a patient’s own T-cells to target myeloma-specific antigens. Though currently reserved for advanced cases, ongoing trials are assessing their potential earlier in the treatment sequence. Oral proteasome inhibitors and second-generation immunomodulators are being developed to improve convenience and reduce adverse effects, especially in long-term maintenance settings.

Which Patient Segments and Healthcare Settings Are Driving Demand?

Relapsed and refractory patients represent the fastest-growing treatment segment, requiring novel agents with new mechanisms of action. Elderly patients and those with comorbidities often require lower-intensity regimens, creating demand for oral or subcutaneous formulations that can be administered outside of hospital settings. Outpatient infusion centers, specialty pharmacies, and home healthcare providers are increasingly involved in care delivery, especially as treatment durations extend over months or years.

Diagnostic improvements are enabling earlier identification and risk stratification, leading to earlier intervention in high-risk patients. Supportive care for managing bone disease, renal dysfunction, and treatment-related side effects is also improving, allowing broader access to combination regimens. Payers and providers are emphasizing value-based care, focusing on therapies that demonstrate long-term disease control with acceptable toxicity profiles. This shift is influencing formulary inclusion and patient access strategies worldwide.

Growth in the Multiple Myeloma Drugs Market Is Driven by Several Factors…

Growth in the multiple myeloma drugs market is driven by several factors. Rising global incidence, particularly in aging populations, is expanding the treatment pool. Continuous innovation in immunotherapies, cell therapies, and targeted agents supports clinical adoption and label expansion. Improved diagnostic precision allows for risk-adapted treatment planning, increasing demand for both frontline and salvage therapies. Shift toward outpatient and home-based treatment delivery boosts use of oral and subcutaneous agents. Growing acceptance of combination regimens and maintenance therapy extends duration of treatment, generating sustained demand. Investment by biopharmaceutical companies in pipeline development and clinical trials further accelerates market expansion across regions.

SCOPE OF STUDY:

The report analyzes the Multiple Myeloma Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Idec
  • bluebird bio, Inc.
  • Bristol-Myers Squibb (Celgene)
  • Cipla Inc.
  • Daiichi Sankyo
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson (Janssen)
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Seagen (Pfizer subsidiary)
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Multiple Myeloma Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Multiple Myeloma Spurs Continuous Development of Novel Therapeutic Agents
    • Advancements in Monoclonal Antibodies and CAR-T Cell Therapies Drive Innovation in Treatment Options
    • FDA Approvals of First-in-Class Drugs Strengthen Competitive Landscape and Accelerate Pipeline Growth
    • Increased Focus on Personalized Medicine Throws Spotlight on Genotype-Specific Therapeutics
    • Growing Use of Combination Therapies Enhances Treatment Efficacy and Sustains Demand for Multi-Drug Regimens
    • Patient Preference for Oral and Targeted Therapies Spurs Development of Convenient Drug Delivery Formats
    • Clinical Trial Expansion and Cross-Border Collaborations Accelerate Access to Experimental Therapies
    • Rising Awareness and Early Diagnosis Improve Patient Eligibility for Advanced Drug Protocols
    • Payer Support for High-Cost Therapies in Oncology Encourages Continued Investment in Premium Drugs
    • Academic and Pharma Partnerships Fuel Discovery of Next-Generation Immunotherapies and Inhibitors
    • Post-Transplant Maintenance Strategies Strengthen Market for Chronic and Long-Term Drug Use
    • Improved Survival Rates Extend Treatment Cycles, Increasing Cumulative Drug Consumption
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multiple Myeloma Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Multiple Myeloma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Multiple Myeloma Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biologic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biologic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biologic Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Multiple Myeloma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Multiple Myeloma Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Multiple Myeloma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Multiple Myeloma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Multiple Myeloma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Multiple Myeloma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Multiple Myeloma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Multiple Myeloma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제